Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 5, Issue 1, 2024

Progress on Novel Therapeutic Drugs for Chronic Heart Failure

Download as PDF

DOI: 10.23977/medsc.2024.050114 | Downloads: 8 | Views: 166

Author(s)

Shixin Kang 1

Affiliation(s)

1 Department of Cardiology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China

Corresponding Author

Shixin Kang

ABSTRACT

This article comprehensively analyzes the existing treatment methods for chronic heart failure (CHF), and focuses on exploring the research progress in new therapeutic drugs in recent years. This article examines the limitations of traditional treatment methods and emphasizes the necessity of developing new drugs. This article mainly evaluated the innovation of SGLT2 (Sodium-dependent Glucose Transporters 2) inhibitors in terms of mechanism, efficacy, and safety, and explored the potential impact of SGLT2 on individualized treatment. In the experimental research stage, it is divided into three experiments: preclinical pharmacological effect evaluation, acute toxicity study, and preliminary therapeutic effect and safety study. In the preclinical pharmacological efficacy evaluation experiment, the average left ventricular ejection fraction (LVEF) of the treatment group was 55%, while the average of the control group was 50%. In acute toxicity research experiments, as the dosage increases, the mortality rate of rats also increases continuously. The mortality rate of the high-dose group reached 70%. In the preliminary clinical efficacy and safety study experiment, the ejection fraction of the treatment group increased from 45% to about 50%, and the quality of life score increased from 70 points to 75 points. The control group showed no significant changes in both indicators. Based on the above data, it can be concluded that SGLT2 inhibitors have potential efficacy and safety in animal models of chronic heart failure and preliminary human clinical trials, and further research is needed to validate these findings.

KEYWORDS

Heart Failure, SGLT2 Inhibitors, Clinical Research, Drug Safety, Drug Efficacy

CITE THIS PAPER

Shixin Kang, Progress on Novel Therapeutic Drugs for Chronic Heart Failure. MEDS Clinical Medicine (2024) Vol. 5: 92-99. DOI: http://dx.doi.org/10.23977/medsc.2024.050114.

REFERENCES

[1] Xia Yi, Li Xuelong, Qiao Fengjie. Observation on the effect of Musk Baoxin Pill combined with recombinant human brain natriuretic peptide in the treatment of ischemic heart failure. Chinese General Medicine, 2024, 21(11): 1876-1879.
[2] Gu Chunling, Xu Min. Application of "5E" rehabilitation intervention program in patients with heart failure. International Journal of Nursing, 2024, 43(01):38-41.
[3] Yuan Yili, Gu Yu. Controversial analysis of the treatment method and concept change of heart failure. Medicine and Philosophy, 2022, 43(22):56-60.
[4] Xu Xiangmin. A brief discussion on the clinical treatment methods and effects of elderly patients with severe heart failure in cardiology. Healthy Women, 2020, 012(022): 68-69.
[5] Yuan Huajing, Xue Yitao. Overview of the treatment of heart failure by bone marrow mesenchymal stem cells based on the theory of heart-kidney intersection. Journal of Shandong University of Traditional Chinese Medicine, 2023, 47(1):106-110.
[6] McDonagh T A, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal, 2021, 42(36): 3599-3726.
[7] Tsutsui H, Ide T, Ito H, et al. JCS/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. Circulation Journal, 2021, 85(12): 2252-2291.
[8] Lala A, Tayal U, Hamo C E, et al. Sex differences in heart failure. Journal of cardiac failure, 2022, 28(3): 477-498.
[9] Terentes-Printzios D, Ioakeimidis N, Rokkas K, et al. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. Nature Reviews Cardiology, 2022, 19(1): 59-74.
[10] Brown E, Heerspink H J L, Cuthbertson D J, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. The Lancet, 2021, 398(10296): 262-276.
[11] De Fronzo R A, Reeves W B, Awad A S. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nature Reviews Nephrology, 2021, 17(5): 319-334.
[12] Nassif M E, Windsor S L, Borlaug B A, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature medicine, 2021, 27(11): 1954-1960.
[13] McGuire D K, Shih W J, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA cardiology, 2021, 6(2): 148-158.
[14] Velliou M, Polyzogopoulou E, Ventoulis I, et al. Clinical pharmacology of SGLT-2 inhibitors in heart failure. Expert Review of Clinical Pharmacology, 2023, 16(2): 149-160.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4545
Visits: 196800

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.